from documents that were available in the public domain. The end product, which Afrigen developed between September and February, is a new jab, so not an exact copy of Moderna’s shot; rather, it’s a jab that is based on the DNA code of Moderna’s vaccine.to make antibodies, but also that the antibodies are good at inactivating the SARS-CoV-2 virus, which causes Covid. Terblanche says these results suggest that the mRNA technology they developed works.
, into a small sample of bacteria to make a starter culture, almost like you would do when making a batch of yoghurt. Disposable overalls protect researchers from coming into contact with bacteria. Picture: Jay Caboz/Bhekisisa. In fact, the development facility at Afrigen spans 380m² — about the size of four two-bedroom townhouses next to one another. A setup of this size can produce, theoretically, about 3-million vials per year, says Caryn Fenner, an executive director at Afrigen. Three-million vials will give 30-million doses .
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Inside SA’s mRNA hub: What it looks like and how it worksAfrigen Biologics, a Cape Town pharmaceutical company, has made Africa’s first Covid jab as part of the World Health Organisation’s mRNA vaccine technology transfer hub. How did it do it and what’s next?
Source: FinancialMail - 🏆 20. / 63 Read more »
Inside SA’s mRNA hub: What it looks like and how it worksAfrigen Biologics, a Cape Town pharmaceutical company, has made Africa’s first Covid jab as part of the World Health Organisation’s mRNA vaccine technology transfer hub. How did it do it and what’s next?
Source: FinancialMail - 🏆 20. / 63 Read more »
Source: dailymaverick - 🏆 3. / 84 Read more »